Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avotermin Dose Ranging for Scar Improvement in Healthy Volunteers
NCT00629811Phase 2Completed
- Sponsor
- Renovo
- Start
- Sep 2006
- Primary completion
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avotermin in cicatrix (2 arms), sponsored by Renovo. Primary endpoint: Optimal concentration and dose regimen of Juvista for the improvement of the resultant scar at Month 7. Started Sep 2006; status: completed.
02
Drugs
avotermin
03
Conditions
cicatrix
Beyond the preview
Go deeper on NCT00629811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00629811.